VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences

---

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

---

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference.

Presentation details can be found below.

Barclays Global Healthcare Conference
Day:	Tuesday, March 9, 2021
Time:	8:00am Eastern Time
Format:	Fireside chat
Webcast Link:	https://kvgo.com/2021-global-healthcare-conference/vyne-therapeutics-2021
H.C. Wainwright Global Life Sciences Conference
Day & Time:	On demand, beginning 7:00am Eastern Time, Tuesday, March 9, 2021
Format:	Fireside chat
Webcast Link:	https://journey.ct.events/view/7534c623-91e5-4fa6-9d64-6dbed8781b9a

About VYNE Therapeutics Inc.VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

CONTACT:Joyce AllaireLifeSci Advisors, LLC646-889-1200jallaire@lifesciadvisors.com 

Andrew SaikChief Financial OfficerVYNE Therapeutics908-731-6180Andrew.Saik@vynetx.com 

Source: VYNE Therapeutics Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Grab to Go Public in Partnership with Altimeter (AGC) for Equity Value of $39.6 Billion
• GT Holdings Corp. Announces Filing of Consolidated Carve-Out Financial Statements
• StorageVault to Acquire 2 Storage Locations for $29.45 Million